WO2004098612A3 - Calcitriol analogs of uses thereof - Google Patents

Calcitriol analogs of uses thereof Download PDF

Info

Publication number
WO2004098612A3
WO2004098612A3 PCT/IB2004/001871 IB2004001871W WO2004098612A3 WO 2004098612 A3 WO2004098612 A3 WO 2004098612A3 IB 2004001871 W IB2004001871 W IB 2004001871W WO 2004098612 A3 WO2004098612 A3 WO 2004098612A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
calcitriol
calcitriol analogs
administrating
aimed
Prior art date
Application number
PCT/IB2004/001871
Other languages
French (fr)
Other versions
WO2004098612A2 (en
Inventor
Alain Moussy
Jean-Pierre Kinet
Original Assignee
Ab Science
Alain Moussy
Jean-Pierre Kinet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science, Alain Moussy, Jean-Pierre Kinet filed Critical Ab Science
Publication of WO2004098612A2 publication Critical patent/WO2004098612A2/en
Publication of WO2004098612A3 publication Critical patent/WO2004098612A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Abstract

The present invention relates to a method of treating mast cells associated diseases comprising administrating calcitriol or analogs thereof to a mammal in need of such treatment. It is also aimed at new analogs and to the combined use of these compounds with a c-kit inhibitor.
PCT/IB2004/001871 2003-05-07 2004-05-07 Calcitriol analogs of uses thereof WO2004098612A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46829503P 2003-05-07 2003-05-07
US60/468,295 2003-05-07
US48022403P 2003-06-23 2003-06-23
US60/480,224 2003-06-23

Publications (2)

Publication Number Publication Date
WO2004098612A2 WO2004098612A2 (en) 2004-11-18
WO2004098612A3 true WO2004098612A3 (en) 2005-02-10

Family

ID=33436754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001871 WO2004098612A2 (en) 2003-05-07 2004-05-07 Calcitriol analogs of uses thereof

Country Status (1)

Country Link
WO (1) WO2004098612A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016323A2 (en) * 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
AU2005216651A1 (en) 2004-03-01 2005-09-09 Bioxell Spa Treatment of interstitial cystitis with vitamin D compounds
EP1755592A1 (en) * 2004-04-20 2007-02-28 AB Science Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
US8088806B2 (en) 2005-05-09 2012-01-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
CA2687817A1 (en) 2007-05-22 2008-12-04 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles
AU2009337184A1 (en) * 2009-01-16 2011-07-28 Anzamed International Limited Medicament for the treatment of pain and inflammation
PL226174B1 (en) * 2011-12-30 2017-06-30 Inst Farm Combination therapy of non-small-cell lung carcinoma
CN104758300A (en) * 2014-01-02 2015-07-08 上海泽生科技开发有限公司 Antibacterial applications of vitamin D and vitamin D composition
CN104095990A (en) * 2014-06-19 2014-10-15 三普药业有限公司 Application of Xinnaoxin capsule to preparation of medicine for improving elder memory
ES2714628B2 (en) * 2017-11-29 2019-10-02 Univ Santiago Compostela Compounds derived from vitamin D
WO2019106214A1 (en) * 2017-11-29 2019-06-06 Universidade De Santiago De Compostela Compounds derived from vitamin d
ES2759698A1 (en) * 2018-11-09 2020-05-11 Univ Santiago Compostela COMPOUNDS DERIVED FROM VITAMIN D (Machine-translation by Google Translate, not legally binding)
CN110623928B (en) * 2019-08-12 2021-12-10 浙江中医药大学 Preparation method of ergosterol and gefitinib combined liposome
WO2023154904A2 (en) * 2022-02-11 2023-08-17 Loma Linda University Compositions and methods for treating acute myeloid leukemia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0579915A1 (en) * 1992-05-20 1994-01-26 F. Hoffmann-La Roche Ag Pharmaceutical composition containing a-cis- o 13-cis-retinoic acid or acitretin and a vitamin D derivative
EP0580968A2 (en) * 1992-05-20 1994-02-02 F. Hoffmann-La Roche Ag Vitamin D3 fluorinated analogs
JPH072674A (en) * 1992-10-08 1995-01-06 Thomas Doure Bunoa Leukemia remedy
US5547947A (en) * 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
US5998394A (en) * 1996-04-05 1999-12-07 Voorhees; John J. Compositions for treating skin conditions by enhancing the activity of 1,25(OH)2 D3 using an RXR ligand and/or a 24-hydroxylase inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0579915A1 (en) * 1992-05-20 1994-01-26 F. Hoffmann-La Roche Ag Pharmaceutical composition containing a-cis- o 13-cis-retinoic acid or acitretin and a vitamin D derivative
EP0580968A2 (en) * 1992-05-20 1994-02-02 F. Hoffmann-La Roche Ag Vitamin D3 fluorinated analogs
JPH072674A (en) * 1992-10-08 1995-01-06 Thomas Doure Bunoa Leukemia remedy
US5547947A (en) * 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
US5998394A (en) * 1996-04-05 1999-12-07 Voorhees; John J. Compositions for treating skin conditions by enhancing the activity of 1,25(OH)2 D3 using an RXR ligand and/or a 24-hydroxylase inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASOU HIROYA ET AL: "19-nor vitamin-D analogs: A new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines", BLOOD, vol. 92, no. 7, 1 October 1998 (1998-10-01), pages 2441 - 2449, XP002293797, ISSN: 0006-4971 *
DATABASE WPI Section Ch Week 199515, Derwent World Patents Index; Class B05, AN 1995-109373, XP002293800 *
GUZEY MERAL ET AL: "Combinational effects of vitamin D3 and detinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 249, no. 3, 28 August 1998 (1998-08-28), pages 735 - 744, XP002293798, ISSN: 0006-291X *
MAKISHIMA MAKOTO ET AL: "Greater synergism of retinoic acid receptor (RAR) agonists with vitamin D3 than that of retinoid X receptor (RXR) agonists with regard to growth inhibition and differentiation induction in monoblastic leukemia cells", BIOCHEMICAL PHARMACOLOGY, vol. 57, no. 5, 1 March 1999 (1999-03-01), pages 521 - 529, XP002293799, ISSN: 0006-2952 *
RUSTIN ET AL: "Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 74, no. 9, 1 November 1996 (1996-11-01), pages 1479 - 1481, XP002079313, ISSN: 0007-0920 *

Also Published As

Publication number Publication date
WO2004098612A2 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2005099680A3 (en) Use of treprostinil to treat neuropathic diabetic foot ulcers
WO2004098612A3 (en) Calcitriol analogs of uses thereof
EP1581169A4 (en) Compositions and methods for the treatment of natural killer cell related diseases
HK1091112A1 (en) Compounds and methods for increasing neurogenesis
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
EP2335722A3 (en) Use of gelsolin to treat infections
IS7684A (en) New compounds, preparations and methods for the treatment of inflammatory diseases and conditions
WO2006063048A3 (en) Ibudilast for treating neuropathic pain and associated syndromes
UA85559C2 (en) Aminobenzophenone compounds
ECSP055844A (en) NEW TRICYCLE COMPOUNDS
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
WO2006063215A3 (en) Methods and compositions for the treatment of pulmonary hypertension of the newborn
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
WO2009130615A3 (en) Use of deuterium oxide as an elastase inhibitor
EP1611120A4 (en) Novel methods for the treatment of inflammatory diseases
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
WO2004028548A3 (en) Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
EP1740221A4 (en) Methods and compositions for the treatment of polycystic diseases
IL178970A0 (en) Haplotype markers and methods of using the same to determine response to treatment
ZA200609220B (en) Method of treating dry eye disorders and uveitis
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
AU9545701A (en) Use of carp inhibitors for the treatment of heart diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase